Tag Archives: welcome
#437791 Is the Pandemic Spurring a Robot ...
“Are robots really destined to take over restaurant kitchens?” This was the headline of an article published by Eater four years ago. One of the experts interviewed was Siddhartha Srinivasa, at the time professor of the Robotics Institute at Carnegie Mellon University and currently director of Robotics and AI for Amazon. He said, “I’d love to make robots unsexy. It’s weird to say this, but when something becomes unsexy, it means that it works so well that you don’t have to think about it. You don’t stare at your dishwasher as it washes your dishes in fascination, because you know it’s gonna work every time… I want to get robots to that stage of reliability.”
Have we managed to get there over the last four years? Are robots unsexy yet? And how has the pandemic changed the trajectory of automation across industries?
The Covid Effect
The pandemic has had a massive economic impact all over the world, and one of the problems faced by many companies has been keeping their businesses running without putting employees at risk of infection. Many organizations are seeking to remain operational in the short term by automating tasks that would otherwise be carried out by humans. According to Digital Trends, since the start of the pandemic we have seen a significant increase in automation efforts in manufacturing, meat packing, grocery stores and more. In a June survey, 44 percent of corporate financial officers said they were considering more automation in response to coronavirus.
MIT economist David Autor described the economic crisis and the Covid-19 pandemic as “an event that forces automation.” But he added that Covid-19 created a kind of disruption that has forced automation in sectors and activities with a shortage of workers, while at the same time there has been no reduction in demand. This hasn’t taken place in hospitality, where demand has practically disappeared, but it is still present in agriculture and distribution. The latter is being altered by the rapid growth of e-commerce, with more efficient and automated warehouses that can provide better service.
China Leads the Way
China is currently in a unique position to lead the world’s automation economy. Although the country boasts a huge workforce, labor costs have multiplied by 10 over the past 20 years. As the world’s factory, China has a strong incentive to automate its manufacturing sector, which enjoys a solid leadership in high quality products. China is currently the largest and fastest-growing market in the world for industrial robotics, with a 21 percent increase up to $5.4 billion in 2019. This represents one third of global sales. As a result, Chinese companies are developing a significant advantage in terms of learning to work with metallic colleagues.
The reasons behind this Asian dominance are evident: the population has a greater capacity and need for tech adoption. A large percentage of the population will soon be of retirement age, without an equivalent younger demographic to replace it, leading to a pressing need to adopt automation in the short term.
China is well ahead of other countries in restaurant automation. As reported in Bloomberg, in early 2020 UBS Group AG conducted a survey of over 13,000 consumers in different countries and found that 64 percent of Chinese participants had ordered meals through their phones at least once a week, compared to a mere 17 percent in the US. As digital ordering gains ground, robot waiters and chefs are likely not far behind. The West harbors a mistrust towards non-humans that the East does not.
The Robot Evolution
The pandemic was a perfect excuse for robots to replace us. But despite the hype around this idea, robots have mostly disappointed during the pandemic.
Just over 66 different kinds of “social” robots have been piloted in hospitals, health centers, airports, office buildings, and other public and private spaces in response to the pandemic, according to a study from researchers at Pompeu Fabra University (Barcelona, Spain). Their survey looked at 195 robot deployments across 35 countries including China, the US, Thailand, and Hong Kong.
But if the “robot revolution” is a movement in which automation, robotics, and artificial intelligence proliferate through the value chain of various industries, bringing a paradigm shift in how we produce, consume, and distribute products—it hasn’t happened yet.
But there’s a more nuanced answer: rather than a revolution, we’re seeing an incremental robot evolution. It’s a trend that will likely accelerate over the next five years, particularly when 5G takes center stage and robotics as a field leaves behind imitation and evolves independently.
Automation Anxiety
Why don’t we finally welcome the long-promised robotic takeover? Despite progress in AI and increased adoption of industrial robots, consumer-facing robotic products are not nearly as ubiquitous as popular culture predicted decades ago. As Amara’s Law says: “We tend to overestimate the effect of a technology in the short run and underestimate the effect in the long run.” It seems we are living through the Gartner hype cycle.
People have a complicated relationship with robots, torn between admiring them, fearing them, rejecting them, and even boycotting them, as has happened in the automobile industry.
Retail robot in a Walmart store. Credit: Bossa Nova Robotics
Walmart terminated its contract with Bossa Nova and withdrew its 1,000 inventory robots from its stores because the company was concerned about how shoppers were reacting to seeing the six-foot robots in the aisles.
With road blocks like this, will the World Economic Forum’s prediction of almost half of tasks being carried out by machines by 2025 come to pass?
At the rate we’re going, it seems unlikely, even with the boost in automation caused by the pandemic. Robotics will continue to advance its capabilities, and will take over more human jobs as it does so, but it’s unlikely we’ll hit a dramatic inflection point that could be described as a “revolution.” Instead, the robot evolution will happen the way most societal change does: incrementally, with time for people to adapt both practically and psychologically.
For now though, robots are still pretty sexy.
Image Credit: charles taylor / Shutterstock.com Continue reading
#437261 How AI Will Make Drug Discovery ...
If you had to guess how long it takes for a drug to go from an idea to your pharmacy, what would you guess? Three years? Five years? How about the cost? $30 million? $100 million?
Well, here’s the sobering truth: 90 percent of all drug possibilities fail. The few that do succeed take an average of 10 years to reach the market and cost anywhere from $2.5 billion to $12 billion to get there.
But what if we could generate novel molecules to target any disease, overnight, ready for clinical trials? Imagine leveraging machine learning to accomplish with 50 people what the pharmaceutical industry can barely do with an army of 5,000.
Welcome to the future of AI and low-cost, ultra-fast, and personalized drug discovery. Let’s dive in.
GANs & Drugs
Around 2012, computer scientist-turned-biophysicist Alex Zhavoronkov started to notice that artificial intelligence was getting increasingly good at image, voice, and text recognition. He knew that all three tasks shared a critical commonality. In each, massive datasets were available, making it easy to train up an AI.
But similar datasets were present in pharmacology. So, back in 2014, Zhavoronkov started wondering if he could use these datasets and AI to significantly speed up the drug discovery process. He’d heard about a new technique in artificial intelligence known as generative adversarial networks (or GANs). By pitting two neural nets against one another (adversarial), the system can start with minimal instructions and produce novel outcomes (generative). At the time, researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology.
He figured GANs would allow researchers to verbally describe drug attributes: “The compound should inhibit protein X at concentration Y with minimal side effects in humans,” and then the AI could construct the molecule from scratch. To turn his idea into reality, Zhavoronkov set up Insilico Medicine on the campus of Johns Hopkins University in Baltimore, Maryland, and rolled up his sleeves.
Instead of beginning their process in some exotic locale, Insilico’s “drug discovery engine” sifts millions of data samples to determine the signature biological characteristics of specific diseases. The engine then identifies the most promising treatment targets and—using GANs—generates molecules (that is, baby drugs) perfectly suited for them. “The result is an explosion in potential drug targets and a much more efficient testing process,” says Zhavoronkov. “AI allows us to do with fifty people what a typical drug company does with five thousand.”
The results have turned what was once a decade-long war into a month-long skirmish.
In late 2018, for example, Insilico was generating novel molecules in fewer than 46 days, and this included not just the initial discovery, but also the synthesis of the drug and its experimental validation in computer simulations.
Right now, they’re using the system to hunt down new drugs for cancer, aging, fibrosis, Parkinson’s, Alzheimer’s, ALS, diabetes, and many others. The first drug to result from this work, a treatment for hair loss, is slated to start Phase I trials by the end of 2020.
They’re also in the early stages of using AI to predict the outcomes of clinical trials in advance of the trial. If successful, this technique will enable researchers to strip a bundle of time and money out of the traditional testing process.
Protein Folding
Beyond inventing new drugs, AI is also being used by other scientists to identify new drug targets—that is, the place to which a drug binds in the body and another key part of the drug discovery process.
Between 1980 and 2006, despite an annual investment of $30 billion, researchers only managed to find about five new drug targets a year. The trouble is complexity. Most potential drug targets are proteins, and a protein’s structure—meaning the way a 2D sequence of amino acids folds into a 3D protein—determines its function.
But a protein with merely a hundred amino acids (a rather small protein) can produce a googol-cubed worth of potential shapes—that’s a one followed by three hundred zeroes. This is also why protein-folding has long been considered an intractably hard problem for even the most powerful of supercomputers.
Back in 1994, to monitor supercomputers’ progress in protein-folding, a biannual competition was created. Until 2018, success was fairly rare. But then the creators of DeepMind turned their neural networks loose on the problem. They created an AI that mines enormous datasets to determine the most likely distance between a protein’s base pairs and the angles of their chemical bonds—aka, the basics of protein-folding. They called it AlphaFold.
On its first foray into the competition, contestant AIs were given 43 protein-folding problems to solve. AlphaFold got 25 right. The second-place team managed a meager three. By predicting the elusive ways in which various proteins fold on the basis of their amino acid sequences, AlphaFold may soon have a tremendous impact in aiding drug discovery and fighting some of today’s most intractable diseases.
Drug Delivery
Another theater of war for improved drugs is the realm of drug delivery. Even here, converging exponential technologies are paving the way for massive implications in both human health and industry shifts.
One key contender is CRISPR, the fast-advancing gene-editing technology that stands to revolutionize synthetic biology and treatment of genetically linked diseases. And researchers have now demonstrated how this tool can be applied to create materials that shape-shift on command. Think: materials that dissolve instantaneously when faced with a programmed stimulus, releasing a specified drug at a highly targeted location.
Yet another potential boon for targeted drug delivery is nanotechnology, whereby medical nanorobots have now been used to fight incidences of cancer. In a recent review of medical micro- and nanorobotics, lead authors (from the University of Texas at Austin and University of California, San Diego) found numerous successful tests of in vivo operation of medical micro- and nanorobots.
Drugs From the Future
Covid-19 is uniting the global scientific community with its urgency, prompting scientists to cast aside nation-specific territorialism, research secrecy, and academic publishing politics in favor of expedited therapeutic and vaccine development efforts. And in the wake of rapid acceleration across healthcare technologies, Big Pharma is an area worth watching right now, no matter your industry. Converging technologies will soon enable extraordinary strides in longevity and disease prevention, with companies like Insilico leading the charge.
Riding the convergence of massive datasets, skyrocketing computational power, quantum computing, cognitive surplus capabilities, and remarkable innovations in AI, we are not far from a world in which personalized drugs, delivered directly to specified targets, will graduate from science fiction to the standard of care.
Rejuvenational biotechnology will be commercially available sooner than you think. When I asked Alex for his own projection, he set the timeline at “maybe 20 years—that’s a reasonable horizon for tangible rejuvenational biotechnology.”
How might you use an extra 20 or more healthy years in your life? What impact would you be able to make?
Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”
If you’d like to learn more and consider joining our 2021 membership, apply here.
(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.
(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)
This article originally appeared on diamandis.com. Read the original article here.
Image Credit: andreas160578 from Pixabay Continue reading
#437126 ‘I’m cheering for ...
Coronavirus quarantine can be lonely, but at one Tokyo hotel converted to accept patients with mild symptoms, a humanoid robot will be there to offer support and encouragement—as well as admonishments and warnings. Continue reading